Terminal
Stocks
Spotlight
News

Stocks
Healthcare
NASDAQ
CYTK

Market Cap: $10.13B

CI

Cytokinetics, Incorporated

CYTK

NASDAQUSD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive Patents Earnings Surprise

Cashu

Markets

By Cashu Markets. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Cashu Markets Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Markets is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Markets is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Markets and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Financials

Profitability

Gross Profit Margin90.34%

EBITDA Margin-6.94%

EBIT Margin-7.05%

Pre-tax Margin-7.84%

Net Profit Margin-7.84%

Earnings Yield-8.54%

Valuation Multiples

Price / Book-11.76

Price / Sales92.72

Price / Earnings-11.54

PEG0.43

Forward PEG0.44

EV / Sales103.68

EV / EBITDA-14.93

EV / Operating Cash Flow-20.94

EV / Free Cash Flow-19.99

Price / Free Cash Flow-17.87

Price / Operating Cash Flow-18.56

Cash Flow & Capital

Free Cash Flow / Share-$4.45

Operating Cash Flow / Share-$4.25

Free Cash Flow Yield-5.59%

Capex / Revenue23.70%

Capex / Operating Cash Flow-4.79%

Capex / Depreciation2.24

Stock Compensation / Revenue83.75%

Dividend Payout Ratio0.00%

Dividend Yield0.00%

Liquidity & Leverage

Current Ratio4.21

Quick Ratio4.21

Cash Ratio0.65

Debt / Assets1.01

Debt / Capital2.79

Debt / Equity-1.56

Long-Term Debt / Capital3.84

Debt / Market Cap11.85%

Net Debt / EBITDA-1.58

Solvency Ratio-0.39

Financial Leverage-1.54

Efficiency & Working Capital

Asset Turnover0.08

Fixed Asset Turnover0.67

Inventory Turnover66.34

Receivables Turnover15.50

Payables Turnover0.41

Days Sales Outstanding23.55

Days Inventory Outstanding5.5

Days Payables Outstanding882.72

Operating Cycle29.05

Cash Conversion Cycle-853.67

Working Capital Turnover0.16

Returns & Quality

Return on Equity1.40%

Return on Assets-65.15%

Return on Invested Capital-56.16%

ROCE-59.60%

Return on Tangible Assets-65.15%

Operating Return on Assets-47.46%

Income Quality0.63

Tax Burden1.00

Interest Burden1.11

Balance Sheet & Intrinsic Metrics

Enterprise Value$10.97B

Invested Capital$797.26M

Working Capital$640.28M

Tangible Asset Value$-826.57M

Net Current Asset Value$-1.26B

Graham Net-Net-$10.35

Book Value / Share-$6.71

Tangible Book Value / Share-$6.71

Cash / Share$6.64

Financial Health Scores

Piotroski Score3

Altman Z-Score-2.50

Revenue$105.82M

EBIT$-745.69M

Market Cap$9.81B

Working Capital$640.28M

Retained Earnings$-3.69B

Total Assets$1.27B

Total Liabilities$2.1B